Disclosed positions
| SPACE EXPLORATION TECHN CORP | SPCX | CLASS A COM STK | $12,789,728,717 | 74,855,020 | SH | None |
| NAVAN INC | NAVN | CL A | $645,361,120 | 28,218,676 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $172,503,421 | 921,099 | SH | None |
| META PLATFORMS INC | META | CL A | $119,716,587 | 212,531 | SH | None |
| FIGMA INC | FIG | CLASS A COM STK | $108,238,042 | 5,983,308 | SH | None |
| BIOAGE LABS INC | BIOA | COM | $79,244,997 | 3,233,170 | SH | None |
| BLOCK INC | XYZ | CL A | $77,268,972 | 1,016,697 | SH | None |
| ERASCA INC | ERAS | COM | $52,441,000 | 2,862,500 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $50,794,394 | 1,702,225 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $32,152,444 | 1,236,157 | SH | None |
| OMADA HEALTH INC | OMDA | COM | $25,322,376 | 1,153,639 | SH | None |
| NAUTILUS BIOTECHNOLOGY INC | NAUT | COM | $16,947,911 | 9,063,054 | SH | None |
| ROBLOX CORP | RBLX | CL A | $14,931,117 | 274,570 | SH | None |
| AKTIS ONCOLOGY INC | AKTS | COM | $13,375,450 | 415,000 | SH | None |
| CAMP4 THERAPEUTICS CORP | CAMP | COM | $9,287,731 | 2,125,339 | SH | None |
| BITGO HOLDINGS INC | BTGO | COM SHS CL A | $3,451,724 | 666,356 | SH | None |
| KAILERA THERAPEUTICS INC | KLRA | COMMON STOCK | $3,084,200 | 140,000 | SH | None |
| GINKGO BIOWORKS HOLDINGS INC | DNA | CL A NEW | $1,075,909 | 108,568 | SH | None |
| IP STRATEGY HOLDINGS INC | IPST | COM | $9,722 | 4,137 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.